Timely diagnosis and treatment of cancer has become increasingly crucial for reducing the prevalence of the disease, and in particular preventing cancer-related deaths. Worldwide, the prevalence and incidence of cancers have been rising rapidly. Despite extensive research in therapies and clinical oncology, the economic burden of the disease hasn’t come down proportionately. Nonetheless, advancements made in molecular tests have enriched clinical oncology, paving way to advent of tumor- or tissue-specific mutations and expression markers for diagnosis. Advancements made in the methods used for molecular analysis and DNA- or RNA-based assays have grown in significance for driving new possibilities in the cancer tissue diagnostics market. Advent of sophisticated proteomic technologies and progress made in immunohistochemistry (IHC) have offered incremental opportunities to players in the cancer tissue diagnostics market.
The study presents a detailed assessment of the major technological advancements, offering insights into key clinical developments. Breakthroughs and innovative techniques that stand up to scrutiny for commercial use in the healthcare industry are highlighted in the study. The research also presents a data-backed evaluation of the impact of regulatory framework and disease epidemiology for opening new avenues.
The driver for modern molecule-oriented techniques in early tumor detection is a key driver for strides in the cancer tissue diagnostics market. DNA- or RNA-based assays have shown promise for diagnosing cancers of unknown primary site. The high risks posed by hereditary cancer syndromes present a massive avenue for R&D in the cancer tissue diagnostics market. For instance, players are eying substantial opportunities in assays that can be used for identifying germ-line mutations in hereditary cancers. A case in point is germ-line mutations in BRCA1 and BRCA2 genes.
Past few decades have seen the massive economic and emotional burden of cancer incidence on patients and among their caregivers. This has spurred tissue diagnostic technologies for molecular diagnosis of hereditary cancer. Extensive efforts have been made by healthcare providers, clinics and hospitals, in raising the burden, especially in case of ovarian and breast cancer. This is a key trend bolstering the growth prospect of the cancer tissue diagnostics market.
Prominent players and aspiring companies to gain a stronghold in the cancer tissue diagnostics market are making steady efforts to move toward precision medicine. Evidently, a number of R&D efforts by them have shown marked bearing on the clinical oncology, such as in breast cancer. Further, diagnostic developers are looking for new targets that can be used to develop cost-effective diagnostics for population screening in the cancer tissue diagnostics market.
A number of projects have emerged where oncology companies are geared toward developing point-of-care diagnostic technology that can be used as non-invasive diagnostic tools at point of care settings. The use of novel biomarkers could open incredible opportunity for the implementation of point-of-care devices in screening programs. Lan-on-a-chip assays might set the tone for innovations in the cancer tissue diagnostics market.
Some of the key players in the cancer tissue diagnostics market are Danaher Corporation, Merck KGaA, Abbott, F. Hoffmann-La Roche Ltd., Aiforia Technologies Oy, OncoStem Diagnostics, HRP Magenta, AND Agilent Technologies Inc.
Globally, healthcare systems have seen spurt of research on novel biomarkers in North America. This have led to massive revenue potential in the North America cancer tissue diagnostics market. Relentless focus on reducing cancer-related deaths has created new revenue streams elsewhere. Asia and Europe are emerging as new hotspots for players in the market.